KalVista Pharmaceuticals, Inc. (KALV)
19.24
+0.08
(+0.42%)
USD |
NASDAQ |
Apr 28, 16:00
26.70
+7.46
(+38.77%)
Pre-Market: 08:39
KalVista Pharmaceuticals Research and Development Expense (TTM) : 51.90M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Intellia Therapeutics, Inc. | 379.07M |
| Recursion Pharmaceuticals, Inc. | 425.27M |
| Tango Therapeutics, Inc. | 130.51M |
| Modular Medical, Inc. | 18.51M |
| Iovance Biotherapeutics, Inc. | 302.62M |